Abstract：
OBJECTIVE: The aim of this study is to investigate the long-term prognosis of food protein--induced allergic proctocolitis (FPIAP) patients, the risk of developing both allergic and gastrointestinal diseases, and to evaluate whether it leads to allergic march.
METHODS: A total of 149 children who were diagnosed with FPIAP and developed tolerance at least 5 years prior to the study and 41 children (with no history of food allergy) as a control group were enrolled. Both groups were re-evaluated for allergic diseases as well as gastrointestinal disorders.
RESULTS: The mean age of diagnosis for the FPIAP group was 4.2 ± 3.0 months, while the mean age of tolerance was 13.9 ± 7.7 months. The mean age of both FPIAP and control groups at the last visit was 101.6 ± 24.4 and 96.3 ± 24.1 months, respectively (P = 0.213). At the final evaluation of both groups, the comorbid allergic disease was significantly higher in the FPIAP group (P < 0.001). There was no significant difference between the two groups in terms of functional gastrointestinal disorders (FGIDs), eosinophilic gastrointestinal diseases, and inflammatory bowel disease (P = 0.198, 0.579, and 0.579, respectively).In the FPIAP group, the allergic disease was significantly higher at the final visit in patients with comorbid allergic disease at diagnosis (P < 0.001). In the FPIAP group, FGID was significantly higher in the group that developed allergic diseases in the future, compared to the group that did not develop allergic diseases in the future (P = 0.034). The proportion of both FGID and allergic diseases was significantly higher in subjects that developed tolerance at >18 months, compared to subjects that developed tolerance at >18 months (P < 0.001 and <0.001, respectively).
CONCLUSIONS: Patients with FPIAP may develop allergic diseases as well as FGID in the long term.
METHODS: A total of 149 children who were diagnosed with FPIAP and developed tolerance at least 5 years prior to the study and 41 children (with no history of food allergy) as a control group were enrolled. Both groups were re-evaluated for allergic diseases as well as gastrointestinal disorders.
RESULTS: The mean age of diagnosis for the FPIAP group was 4.2 ± 3.0 months, while the mean age of tolerance was 13.9 ± 7.7 months. The mean age of both FPIAP and control groups at the last visit was 101.6 ± 24.4 and 96.3 ± 24.1 months, respectively (P = 0.213). At the final evaluation of both groups, the comorbid allergic disease was significantly higher in the FPIAP group (P < 0.001). There was no significant difference between the two groups in terms of functional gastrointestinal disorders (FGIDs), eosinophilic gastrointestinal diseases, and inflammatory bowel disease (P = 0.198, 0.579, and 0.579, respectively).In the FPIAP group, the allergic disease was significantly higher at the final visit in patients with comorbid allergic disease at diagnosis (P < 0.001). In the FPIAP group, FGID was significantly higher in the group that developed allergic diseases in the future, compared to the group that did not develop allergic diseases in the future (P = 0.034). The proportion of both FGID and allergic diseases was significantly higher in subjects that developed tolerance at >18 months, compared to subjects that developed tolerance at >18 months (P < 0.001 and <0.001, respectively).
CONCLUSIONS: Patients with FPIAP may develop allergic diseases as well as FGID in the long term.
摘要：
目的：本研究的目的是探讨食物蛋白诱导的过敏性直肠结肠炎（FPIAP）患者的长期预后，患过敏性和胃肠道疾病的风险，并评估是否会导致过敏游行。
方法：共纳入149名在研究前至少5年被诊断为FPIAP并形成耐受性的儿童和41名儿童（无食物过敏史）作为对照组。两组均重新评估过敏性疾病以及胃肠道疾病。
结果：FPIAP组的诊断平均年龄为4.2±3.0个月，而平均耐受年龄为13.9±7.7个月。FPIAP组和对照组在最后一次就诊时的平均年龄分别为101.6±24.4和96.3±24.1个月，分别为(P=0.213)。在两组的最终评估中，在FPIAP组中,过敏性疾病的合并症发生率明显增高(P<0.001).两组在功能性胃肠病(FGIDs)方面无显著差异,嗜酸性粒细胞性胃肠道疾病，和炎症性肠病（分别为P=0.198、0.579和0.579）。在FPIAP组中，诊断时合并过敏性疾病的患者在最后一次访视时过敏性疾病显著增高(P<0.001).在FPIAP组中，FGID在将来发生过敏性疾病的组中明显更高，与未来未发生过敏性疾病的组相比（P=0.034）。FGID和过敏性疾病的比例在>18个月时形成耐受性的受试者中明显更高，与在>18个月时形成耐受性的受试者相比（分别为P<0.001和<0.001）。
结论：FPIAP患者可能长期发展为过敏性疾病和FGID。
方法：共纳入149名在研究前至少5年被诊断为FPIAP并形成耐受性的儿童和41名儿童（无食物过敏史）作为对照组。两组均重新评估过敏性疾病以及胃肠道疾病。
结果：FPIAP组的诊断平均年龄为4.2±3.0个月，而平均耐受年龄为13.9±7.7个月。FPIAP组和对照组在最后一次就诊时的平均年龄分别为101.6±24.4和96.3±24.1个月，分别为(P=0.213)。在两组的最终评估中，在FPIAP组中,过敏性疾病的合并症发生率明显增高(P<0.001).两组在功能性胃肠病(FGIDs)方面无显著差异,嗜酸性粒细胞性胃肠道疾病，和炎症性肠病（分别为P=0.198、0.579和0.579）。在FPIAP组中，诊断时合并过敏性疾病的患者在最后一次访视时过敏性疾病显著增高(P<0.001).在FPIAP组中，FGID在将来发生过敏性疾病的组中明显更高，与未来未发生过敏性疾病的组相比（P=0.034）。FGID和过敏性疾病的比例在>18个月时形成耐受性的受试者中明显更高，与在>18个月时形成耐受性的受试者相比（分别为P<0.001和<0.001）。
结论：FPIAP患者可能长期发展为过敏性疾病和FGID。
